Jane Street’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.09M Buy
42,900
+36,400
+560% +$2.07M ﹤0.01% 4292
2025
Q4
$275K Sell
6,500
-13,321
-67% -$746K ﹤0.01% 9037
2025
Q3
$1.13M Buy
+19,821
New +$656K ﹤0.01% 6057
2023
Q4
Sell
-1,047
Closed -$9.35K 9604
2023
Q3
$9.35K Buy
+1,047
New +$10.1K ﹤0.01% 8391
2022
Q4
Sell
-8,333
Closed -$400K 9794
2022
Q3
$400K Sell
8,333
-2,334
-22% -$139K ﹤0.01% 7097
2022
Q2
$608K Sell
10,667
-16,306
-60% -$1.03M ﹤0.01% 6385
2022
Q1
$2.18M Sell
26,973
-1,294
-5% -$192K ﹤0.01% 4586
2021
Q4
$5.73M Buy
28,267
+6,580
+30% +$1.43M ﹤0.01% 2647
2021
Q3
$5.84M Buy
21,687
+7,920
+58% +$1.9M ﹤0.01% 2499
2021
Q2
$3.54M Buy
13,767
+11,260
+449% +$3.12M ﹤0.01% 3255
2021
Q1
$752K Sell
2,507
-666
-21% -$207K ﹤0.01% 6019
2020
Q4
$809K Sell
3,173
-3,240
-51% -$837K ﹤0.01% 5008
2020
Q3
$1.6M Sell
6,413
-1,247
-16% -$392K ﹤0.01% 3371
2020
Q2
$2.66M Buy
+7,660
New +$2.39M ﹤0.01% 2670
2018
Q3
Sell
-3,520
Closed -$2.58M 5508
2018
Q2
$2.58M Buy
3,520
+3,093
+724% +$3.57M 0.01% 1650
2018
Q1
$680K Buy
427
+127
+42% +$164K ﹤0.01% 3126
2017
Q4
$269K Buy
+300
New +$177K ﹤0.01% 3888
2017
Q2
Sell
-920
Closed -$324K 4692
2017
Q1
$324K Buy
+920
New +$207K ﹤0.01% 3335
2016
Q1
Sell
-693
Closed -$175K 4469
2015
Q4
$175K Buy
+693
New +$143K ﹤0.01% 3662
2015
Q3
Sell
-680
Closed -$128K 3967
2015
Q2
$128K Buy
+680
New +$117K ﹤0.01% 3379

Other funds holding NKTR

Jane Street's NKTR Position: Q1 2026 in Review

Jane Street reduced its Nektar Therapeutics (NKTR) stake by 48% in Q1 2026, selling an estimated $6.02M and leaving 112,652 shares worth $8.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2806.

Jane Street first reported a position in NKTR in Q2 2013 and has held it in 33 quarters since. The position peaked at $16.4M in Q2 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Jane Street held 112,652 shares of Nektar Therapeutics worth $8.11M as of Q1 2026.
  • Jane Street sold 105,685 Nektar Therapeutics shares in Q1 2026, an estimated $6.02M.
  • Nektar Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #2806 holding.
  • Jane Street first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 33 quarters since.
  • Jane Street's Nektar Therapeutics position peaked at $16.4M in Q2 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.